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Summary
Objectives: It has been reported that the overlap of sirolimus-eluting stents (SESs) is associated
with greater in-stent late lumen loss and more angiographic restenosis. The purpose of this study
was to evaluate whether the site of such overlap shows increased or decreased late lumen loss
as assessed by quantitative coronary angiogram.
Methods and results: We compared 7-month angiographic late lumen loss at the site of over-
lap in patients with multiple overlapping stents (overlap SES group, n = 48) to that in patients
with single stents (single SES group, n = 144). With regard to baseline angiographic characteris-
tics and procedural results, there were signiﬁcant differences between the overlap SES group
and the single SES group in lesion complexity, lesion length and reference diameter, minimal
lumen diameter, and mean stent length. In-stent late lumen loss at the 7-month follow-up
did not differ signiﬁcantly between the two groups (overlap SES 0.25± 0.61mm vs. single SES
0.10± 0.55mm, p = 0.11). Furthermore, the site of overlap in the overlap SES group did not show
greater late lumen loss compared to the stented area in the single SES group (0.17± 0.55mm
vs. 0.10± 0.55mm, p = 0.43). The overlap SES group tended to be associated with an increase
∗ Corresponding author. Tel.: +81 92 801 1011; fax: +81 92 865 2692.
E-mail address: saku-k@fukuoka-u.ac.jp (K. Saku).
0914-5087/$ — see front matter © 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.jjcc.2010.11.005
188 Y. Takamiya et al.
in binary restenosis compared with the single SES group (22.8% vs. 12.8%, p = 0.08), while this
value was 4.2% at the site of overlap. There were no signiﬁcant differences in death, myocardial
infarction, target lesion revascularization, or stent thrombosis between the two groups. In addi-
tion, stent length was the most independent factor of late lumen loss in the overlap SES group
by multivariate logistic analysis, whereas it was not an independent factor of late lumen loss of
the SES overlap segment.
Conclusions: The site of overlap of overlapping SES dose not associate with greater late lumen loss
or a higher in-stent binary restenosis rate compared to single SES implantation. The overlapping
se in
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ous variables between groups were examined by Student’s
t-test or Wilcoxon’s rank-sum test. Multivariate analysis wasof SES by itself did not increa
© 2011 Japanese College of C
ntroduction
he incidence of in-stent restenosis (ISR) has dramati-
ally decreased worldwide since the introduction of the
ypherTM sirolimus-eluting stent (SES) (Cordis Corporation,
iami, FL, USA) [1—3]. However, diabetes mellitus, periph-
ral artery disease, long stent length, and small coronary
essels increase the incidence of ISR with SES [4—6]. Addi-
ionally, it has been reported that the overlap of SES is
ssociated with greater late loss in-stent and more angio-
raphic ISR [7,8]. It is unknown whether the site of overlap
s associated with a greater late lumen loss in overlapping
ES. Therefore, the purpose of this study was to evaluate
hether the site of overlap of overlapping SES increases
ngiographic late lumen loss, or rather decreases it.
ethods
atients
wo hundred thirteen patients with angina pectoris or silent
yocardial ischemia were treated with SES at Fukuoka Uni-
ersity Hospital between October 2004 and November 2007.
total of 69 of 213 patients with SES implantation received
ultiple stents because of excessive target lesion length,
ncomplete target lesion coverage, or stent margin dis-
ection. However, 21 of 69 patients were excluded from
his study because they did not receive overlapping SES
mplantation. Forty-eight of these patients received mul-
iple overlapping SES implantation. In addition, patients
ith acute myocardial infarction (MI) were excluded from
his study. The use of intravascular ultrasound (IVUS) and
ost-stent dilatation with a high-pressure balloon was left
o the operator’s discretion. Aspirin was continued for an
ndeﬁnite period and 200mg/day ticlopidine or 75mg/day
lopidogrel was continued for at least 7 months after the
rocedure. Follow-up angiogram was obtained 7 months
fter SES implantation. Therefore, we compared 7-month
ngiographic late lumen loss and ISR at the site of over-
ap in patients with multiple overlapping stents (overlap SES
roup, n = 48) to those in patients with a single stent (single
ES group, n = 144).
Major adverse cardiac events [death, MI, target lesion
evascularization (TLR), and stent thrombosis] were also
valuated in all patients at the 7-months follow-up. MI was
eﬁned as either the development of pathological Q waves in
t least two contiguous leads with or without elevated car-
iac enzymes, or the absence of pathological Q waves and
levation of the creatine kinase level to more than twice
p
v
a
e
t-stent late lumen loss.
ology. Published by Elsevier Ltd. All rights reserved.
he upper limit of normal in the presence of an elevated
reatine kinase-MB level. Stent thrombosis was deﬁned as
n acute coronary syndrome with angiographic documenta-
ion of vessel occlusion or thrombosis within or adjacent to a
reviously stented segment. In the absence of angiography,
tent thrombosis was conﬁrmed by acute MI in the distri-
ution of the treated vessel or death resulting from cardiac
auses within 30 days. The ethics committee of Fukuoka Uni-
ersity Hospital approved this study and written informed
onsent was obtained from each patient.
uantitative coronary angiogram
uantitative coronary angiograms (QCAs) were performed
n all qualifying angiograms at the angiographic core labora-
ory in Fukuoka University Hospital using CMS (Medis, Leiden,
he Netherlands). Pre- and post-intervention and follow-up
CA analyses were performed by dividing the stented lesion
nto 5 segments: (1) proximal edge (5-mm segment proximal
o the proximal stent); (2) proximal stent (segment cov-
red only by the proximal stent); (3) overlap (segment with
verlapped stent struts); (4) distal stent (segment covered
nly by the distal stent); and (5) distal edge (5-mm seg-
ent distal to the distal stent) (Fig. 1) [9]. Restenosis was
eﬁned as >50% diameter stenosis at follow-up angiogram.
ate lumen loss was calculated as the difference in the min-
mal lumen diameter between the end of the procedure and
ollow-up. Mean stent diameter indicated the mean diame-
er in the stent area, and minimum stent diameter was the
inimal lumen diameter in the stent area. In addition, refer-
nce stent diameter was the reference diameter in the stent
rea. A laboratory member blindly carried out the analyses
ithout knowledge of the stent procedure.
tatistical analysis
tatistical analysis was performed using the SAS software
ackage (version 9.1, Statistical Analysis System, SAS Insti-
ute Inc., Cary, NC, USA) at Fukuoka University. Categorical
ariables were compared between groups by a chi-square
nalysis or Fisher’s exact test. The differences in continu-erformed by a logistic regression analysis for independent
ariables that were related to values of late lumen loss. Data
re presented as the mean and standard deviation. Differ-
nces were considered to be statistically signiﬁcant when
he p-value was less than 0.05 unless indicated otherwise.
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Results
Baseline patient characteristics were similar between the
overlap and single groups (Table 1), except for complex
lesion (B2/C) (97.9% vs. 74.7%, respectively, p < 0.0001).
More than half of the patients in both groups had diabetes
mellitus, hypertension, or dyslipidemia.
Baseline angiographic characteristics and procedural
results are shown in Table 2. There were signiﬁcant differ-
ences between the groups with respect to lesion length and
reference diameter, minimal lumen diameter in-segment,
in-lesion diameter stenosis (%), and mean stent length,
which indicated that the overlap SES group had more
complex lesions. The diameter of the post-stented seg-
ment (mean stent diameter) was similar in the two groups
(2.73± 0.28mm in the overlap SES group and 2.84± 0.54mm
in the single SES group), while this value was 3.89± 1.67mm
at the site of overlap. The length of the site of overlap in
the overlap SES group by QCA was 2.88± 0.32mm. There
were no differences in the use of calcium-channel blockers,
-blockers, diuretic agents, angiotensin II receptor block-
ers, statins, or nicorandil between the two groups. However,
nitrates were used more frequently in the overlap SES group
than in the single SES group (48% vs. 27%, respectively,
p = 0.016, data not tabulated).Table 3 shows the 7-month angiographic and clinical out-
comes. One patient in the single stent group underwent
follow-up angiography at 4 months because of chest pain,
and this conﬁrmed restenosis. There was no signiﬁcant dif-
ference in in-stent late lumen loss between the overlap
M
I
e
hQCA, quantitative coronary angiogram.
nd single SES groups (0.25± 0.61mm vs. 0.10± 0.55mm,
espectively, p = 0.11). In addition, although 79% of the
atients in the overlap group received IVUS, IVUS use did
ot correlate with in-stent late lumen loss or late lumen loss
t the overlap site (p = 0.723 and p = 0.677, respectively). It
lso was not associated with in-stent restenosis (p = 0.420).
he site of overlap did not show greater late lumen loss than
he stented area in either the overlap SES group or single SES
roup (0.17± 0.55mm vs. 0.25± 0.61mm, 0.17± 0.55mm
s. 0.10± 0.55mm, p = 0.51 and p = 0.43, respectively). Fur-
hermore, in-stent diameter stenosis of the overlap site
as lower than that of the stented area in both the over-
ap SES group and the single SES group (7.4% vs. 28.7% vs.
7.6%, respectively, p < 0.004). On the other hand, there
ere no signiﬁcant differences between the overlap site in
he overlap SES group and the single SES group with regard
o reference stent diameter or the mean stent diameter. The
SR rate in the overlap SES group tended to be higher than
hat in the single SES group (22.8% vs. 12.8%, respectively,
= 0.08), while this value was 4.2% at the site of overlap.
ne patient died from acute MI by stent thrombosis prob-
bly due to the discontinuation of anti-platelet medication
ecause of the operation. However, the groups showed simi-
ar TLR (14.6% in the overlap SES group vs. 9.1% in the single
ES group, p = 0.30).
ISR patterns in the overlap SES group according to the
ehran classiﬁcation are shown in Fig. 2: 2 (18%) had focal
SR in the overlap site, 4 (36%) had focal ISR in the stented
dge, 3 (28%) had focal ISR in a non-overlap site, and 2 (18%)
ad total occlusion in the stented segment. There were
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Table 1 Baseline patient and angiographic characteristics.
Single group (n = 144) Overlap group (n = 48) p-Value
Age (years) 64.7± 10.0 65.9± 8.8 0.431
Male (%) 83.6 83.3 0.960
BMI (kg/m2) 23.8± 3.2 24.5± 2.3 0.181
Smoking (%) 60.6 58.3 0.777
Diabetes mellitus (%) 57.6 56.3 0.870
Hypertension (%) 67.9 75.0 0.345
Dyslipidemia (%) 69.7 77.1 0.319
LVEF (%) 61.2± 12.2 64.0± 11.6 0.181
Prior MI (%) 35.9 25.5 0.181
ASO (%) 12.4 15.2 0.609
UAP (%) 14.5 16.7 0.720
Target vessel (%)
LAD/RCA/LCX 48.5/26.7/24.8 58.3/22.9/18.8 0.530
Complex (B2/C) lesion (%) 74.7 97.9 <0.001
Bifurcation lesion (%) 32.7 39.6 0.378
Calciﬁed lesion (severe) (%) 11.5 12.5 0.860
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BMI, body mass index; LVEF, left ventricular ejection fraction; MI,
angina pectoris; LAD, left anterior descending artery; RCA, right c
o signiﬁcant differences in death, MI, or stent thrombosis
etween the two groups during 7 months of follow-up.
Table 4 shows the variables that were associated with ISR
n the two groups. In the overlap SES group, patients with
SR tended to have a smaller mean reference stent diameter,
ower stent diameter, and longer stent length and had signif-
cantly smaller minimal lumen diameter in-stent and mean
iameter of the overlap site after the procedure than those
ithout ISR. In addition, multivariate logistic analysis was
erformed to identify factors that determined late lumen
oss in the overlap SES group (Table 5). Stent length, but not
inimal lumen diameter or length overlapped site, was the
ost signiﬁcant independent factor of late lumen loss in the
verlap SES group. On the other hand, stent length was not
i
s
S
i
Table 2 Procedural results.
Single group (n = 144) Over
Pre-procedure
Lesion length (mm) 15.95 ± 6.78 29.5
Reference diameter (mm) 2.51 ± 0.49 2.1
MLD in-segment (mm) 0.82 ± 0.40 0.5
In-lesion diameter stenosis (%) 67.11 ± 16.1 74.4
Post-procedure
MLD in-segment (mm) 1.89 ± 0.47 1.6
Mean stent length (mm) 19.98 ± 5.24 37.4
Mean stent diameter (mm) 2.84 ± 0.54 2.7
Min stent diameter (mm) 2.37 ± 0.42 2.1
Diameter stenosis in-stent (%) 13.86 ± 11.5 18.3
Balloon artery ratio 1.13 ± 0.21 1.2
Stent-artery ratio 1.47 ± 0.78 1.5
Max balloon pressure (atm) 17.07 ± 2.77 17.1
MLD, minimal lumen diameter.
* p < 0.001 vs. single and overlap groups.8.3 0.470
cardial infarction; ASO, atherosclerosis obliterans; UAP, unstable
ary artery; LCX, left circumﬂex coronary artery.
n independent factor of late lumen loss of the SES overlap
egment (Table 6).
iscussion
here have been few reports on angiographic data regarding
he site of overlap of multiple SES. In our study, the over-
ap site had a larger minimal stent diameter and a smaller
n-stent diameter stenosis at follow-up compared to the
tented area in both the overlap SES group and the single
ES group.
Our results indicate that stent overlap is unlikely to
ncrease in-stent diameter stenosis. Overlapping of SES
lap group (n = 48) p-Value
Single vs. overlap Overlapped site
6 ± 13.96 <0.001
8 ± 0.36 <0.001
8 ± 0.31 <0.001
5 ± 14.01 0.005
9 ± 0.38 0.007 2.68 ± 0.30*
9 ± 9.36 <0.001 2.88 ± 0.32*
3 ± 0.28 0.059 3.89 ± 1.67*
6 ± 0.36 0.001 2.68 ± 0.30*
9 ± 8.86 0.005 3.13 ± 7.29*
2 ± 0.59 0.299
0 ± 0.90 0.795
0 ± 2.60 0.860 17.10 ± 2.60
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Table 3 Seven-month angiographic and clinical outcomes.
Single (1)
(n = 144)
Overlap
(2) (n = 48)
p-Value Overlap site
(3) (n = 48)
p-Value
(1) vs. (2) (1) vs. (3) (2) vs. (3)
Reference stent diameter (mm) 2.77± 0.54 2.69± 0.35 0.338 2.77± 0.37 0.999 0.289
Mean stent diameter (mm) 2.78± 0.51 2.73± 0.32 0.502 2.80± 0.64 0.766 0.330
Min stent diameter (mm) 2.28± 0.60 1.91± 0.73 <0.001 2.51± 0.64 0.021 <0.001
In-stent late lumen loss (mm) 0.10± 0.55 0.25± 0.61 0.108 0.17± 0.55 0.433 0.506
In-stent diameter stenosis (%) 17.60± 15.02 28.74± 25.49 0.006 7.40± 13.30 0.004 <0.001
In-stent restenosis (%) 12.8 22.8 0.085 4.2 0.004 <0.001
MACE, n (%) 16 (9.7) 7 (14.6) 0.340
Death, n (%) 1 (0.6) 0
Q wave MI, n (%) 0 0
TLR, n (%) 15 (9.1) 7 (14.6) 0.297
Stent thrombosis, n (%) 0 0
MACE, major adverse coronary event; MI, myocardial infarction; TLR, target lesion revascularization; SES, sirolimus-eluting stent. (1)
Single SES group, (2) overlap SES group and (3) overlap site in the overlap SES group.
Figure 2 In-stent restenosis patterns in the overlap sirolimus-eluting stent group according to the Mehran classiﬁcation.
Table 4 Variables correlate (post-PCI) with the ISR cases in the two groups.
Single Overlap
ISR(−) ISR(+) p-Value ISR(−) ISR(+) p-Value
Diabetes mellitus (%) 55.9 71.3 0.180 54.1 63.6 0.574
Prior myocardial infarction (%) 35.9 33.3 0.818 22.2 36.4 0.347
Arteriosclerosis obliterans (%) 10.0 23.8 0.078 8.6 36.4 0.046
Lesion length (mm) 16.09± 7.01 15.50± 4.76 0.717 28.81± 14.05 32.56± 14.99 0.477
MLD in-segment (mm) 1.88± 0.46 1.95± 0.53 0.509 1.75± 0.37 1.50± 0.36 0.060
Reference stent diameter (mm) 2.76± 0.44 2.83± 0.45 0.481 2.69± 0.31 2.48± 0.39 0.068
Mean stent diameter (mm) 2.85± 0.56 2.84± 0.40 0.990 2.77± 0.28 2.61± 0.27 0.090
MLD in-stent (mm) 2.37± 0.41 2.40± 0.50 0.744 2.22± 0.35 1.95± 0.31 0.029
Stent length (mm) 19.94± 4.76 20.54± 7.87 0.623 36.2± 9.0 42.0± 9.7 0.069
Mean diameter overlap site (mm) 2.94± 0.30 2.70± 0.33 0.031
MLD overlapped site (mm) 2.72± 0.27 2.52± 0.35 0.051
PCI, percutaneous coronary intervention; ISR, in-stent restenosis; MLD, minimal lumen diameter.
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Table 5 Predictors of late lumen loss in the overlap SES group in angiographic factors at follow-up by multiple logistic regression.
Coefﬁcient Standard error Odds ratio (95% CI) p-Value
IVUS −0.6355 1.0178 0.530 (0.07—3.89) 0.53
Post dilatation 0.3118 0.7561 1.366 (0.31—6.01) 0.68
MLD in-segment 1.8663 1.2396 6.465 (0.57—73.4) 0.13
Mean stent diameter −0.6787 2.0709 0.507 (0.01—29.4) 0.74
MLD overlapped site 0.1646 1.7526 1.179 (0.04—36.6) 0.93
Length overlapped site 0.4825 0.2693 1.620 (0.96—2.75) 0.07
Stent length 0.1499 0.0583 1.162 (1.04—1.30) 0.01
SES, sirolimus-eluting stent; IVUS, intravascular ultrasound; MLD, minimal lumen diameter.
Table 6 Predictors of late lumen loss of the SES overlap segment in angiographic factors at follow-up by multiple logistic
regression.
Coefﬁcient Standard error Odds ratio (95% CI) p-Value
IVUS 0.4972 0.9327 1.644 (0.26—10.2) 0.594
Post dilatation −0.0965 0.6680 1.366 (0.25—3.36) 0.885
Min stent diameter 1.1125 1.5849 3.042 (0.14—68.0) 0.483
Mean stent diameter −1.3210 2.5255 0.267 (0.01—37.7) 0.601
Min overlap diameter 0.3385 2.0665 1.403 (0.02—80.5) 0.870
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SES, sirolimus-eluting stent; IVUS, intravascular ultrasound.
ay cause a high drug concentration of the drug at the
verlap site, and this might strongly suppress in-stent
iameter stenosis. Several studies have demonstrated that
VUS-derived lumen dimension after stent deployment is a
onsistent predictor of ISR [10,11]. In this study, 38 (79%)
atients in the overlap group received IVUS guidance, and
ost-dilatation of the overlap site was performed using a
igh-pressure balloon. Although this might be associated
ith the small late loss at the overlap site, IVUS use did not
orrelate with in-stent late lumen loss or late lumen loss at
he overlap site.
It has been reported that SESs have more ISR at the
tented edge than bare-metal stents, and a long coronary
esion must be fully covered by SESs [1]. In addition, it is
ractically difﬁcult for the operator to manually align the
ES positions to achieve perfect tandem alignment in a beat-
ng heart with systolic and diastolic motion of the catheter
ithin the coronary artery. Therefore, stent overlap is more
cceptable than a gap with multiple stents. The efﬁcacy
nd safety of overlapping SES have been reported in sev-
ral trials [7]. The peak blood concentration of sirolimus
fter overlapping SES implantation has been shown to be far
ower than the effective concentration of sirolimus when it
s administrated orally as an immunosuppressive agent [12].
lthough the risk of stent thrombosis after SES implantation
as been related to stent length in pooled analyses including
0 randomized SES studies [13], in the present study there
ere no cases of cardiac death, MI, TLR, or late stent throm-
osis in the overlap group during 7 months of follow-up. In
ddition, no aneurysm formation was observed at the over-
ap site. These results suggest the safety of overlapping SES
mplantation.
In this study, the site of overlap of overlapping SES
as not associated with greater late lumen loss or a
T
o
a
R1.062 (0.70—1.62) 0.781
1.007 (0.94—1.09) 0.846
igher in-stent binary restenosis rate compared to single
ES implantation. There is a conﬂicting report regarding
ate lumen loss, the risk of TLR, and the composite risk
f death or MI [14]. These parameters were all increased
n patients with drug-eluting stent overlap compared with
he no-overlap stent and single stent groups. These differ-
nces in the subjects and angiographic characteristics could
ccount for the discrepancies between the studies. Our sub-
ects were older and had higher percentages of diabetes
ellitus and complex lesions, and a greater lesion length
han the subjects in the previous report [14].
tudy limitations
lthough IVUS provides more detailed information regard-
ng neointima formation, it was performed only in selected
atients in this study.
onclusions
he site of overlap of overlapping SES is not associated with a
reater late lumen loss or a higher in-stent binary restenosis
ate compared to the single SES implantation. The over-
apping of SES itself dose not increase in-stent late lumen
oss.
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